Sanofi and Regeneron boost investment in cancer drug cemiplimab

PARIS (Reuters) - France's Sanofi and U.S Regeneron said on Monday they would inject an additional $1 billion in the development of cemiplimab, an antibody that could, if successful, be used to treat a wide range of cancers.